Advocate General Ruiz-Jarabo has delivered a non-binding opinion to the European Court of Justice (ECJ), finding that GlaxoSmithKline Plc (GSK) abused its dominant position by limiting distribution of certain pharmaceuticals to Greek wholesalers. This case, which was referred to the ECJ by a Greek national court, arose after GSK began to supply certain drugs to hospitals and pharmacies in Greece, bypassing Greek wholesalers. GSK was aware that Greek wholesalers were re-exporting GSK’s drugs from Greece, where drug prices are low, to Member States with higher drug reimbursement rates, a practice known as parallel trade. While GSK eventually resumed distribution to Greek wholesalers, GSK only supplied quantities sufficient for the Greek domestic market. The Advocate General concluded that GSK unjustifiably used its dominance to prevent parallel trade, rejecting the argument that state intervention in pharmaceutical markets justified GSK’s conduct. The ECJ will consider the Advocate General's Opinion and render its own judgment.